Meeting Abstract

Evaluation of Seralutinib Treatment Effect Across Four Risk Tools in the TORREY Study in Pulmonary Arterial Hypertension (PAH)


AutorenlisteBenza, R. L.; Osterhout, R.; Hoffman, S.; Zamanian, R. T.; Hemnes, A. R.; Channick, R. N.; Chin, K. M.; Frantz, R. P.; Ghofrani, A.; Howard, L. S.; McLaughlin, V. V.; Vachiery, J.; Zisman, L. S.; Cravets, M.; Bruey, J.; Roscigno, R. F.; Mottola, D.; Aranda, R.; Sitbon, O.

Jahr der Veröffentlichung2024

SeitenS86-S87

ZeitschriftThe Journal of Heart and Lung Transplantation

Bandnummer43

Heftnummer4

ISSN1053-2498

eISSN1557-3117

Konferenz44th Annual Meeting and Scientific Sessions Conference of the International-Society-for-Heart-and-Lung-Transplantation (ISHLT)

VerlagElsevier



Zitierstile

Harvard-ZitierstilBenza, R., Osterhout, R., Hoffman, S., Zamanian, R., Hemnes, A., Channick, R., et al. (2024) Evaluation of Seralutinib Treatment Effect Across Four Risk Tools in the TORREY Study in Pulmonary Arterial Hypertension (PAH), The Journal of Heart and Lung Transplantation, 43(4), pp. S86-S87

APA-ZitierstilBenza, R., Osterhout, R., Hoffman, S., Zamanian, R., Hemnes, A., Channick, R., Chin, K., Frantz, R., Ghofrani, A., Howard, L., McLaughlin, V., Vachiery, J., Zisman, L., Cravets, M., Bruey, J., Roscigno, R., Mottola, D., Aranda, R., & Sitbon, O. (2024). Evaluation of Seralutinib Treatment Effect Across Four Risk Tools in the TORREY Study in Pulmonary Arterial Hypertension (PAH). The Journal of Heart and Lung Transplantation. 43(4), S86-S87.


Zuletzt aktualisiert 2025-01-04 um 22:40